AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 123 min read$NYC

American Strategic Investment Co. (NYC): Results of Operations and Financial Condition

American Strategic Investment Co. (NYC) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.2 3 ex992-asicsupplementalinfo.htm EX-99.2 Document EXHIBIT 99.2 American Strategic Investment Co. Supplemental Information Quarter ended June 30, 2026 (unaudited) American Strategic Investment Co. Supplemental Information Quarter ended June 30, 2026 (Unaudited) Table of Co

Original reporting
SEC EDGAR 8-K
Published Aug 12, 2026, 10:03 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NYC
Neutral
low confidence
Mentioned
$NYC
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NYCNeutralLow
01

Why it matters

The excerpt emphasizes definitions and forward-looking risks (REIT termination benefits, ability to acquire assets, macro and geopolitical risks, NYSE continued listing risk) but does not disclose the quarter’s specific operating or balance sheet outcomes.

02

Market read

Traders should treat this as a filing to review for updated quarter metrics and balance sheet changes; the excerpt alone does not provide the numbers needed for a decision.

03

What to watch

Key trading cues likely sit in the omitted sections (consolidated statements, debt overview, lease expirations, top tenants, and any changes tied to the REIT termination), which are not included in the provided text.

Relevance 7/10Novelty 3/10Timing: filed today, 8-K supplemental info for quarter ended June 30, 2026

Background

The filing is an SEC Form 8-K (Item 2.02) attaching Exhibit 99.2 supplemental information for the quarter ended June 30, 2026, including non-GAAP metrics and forward-looking risk factors.

Company-level read

Ticker impact

$NYCNeutralLow confidence
Context

American Strategic Investment Co. filed an 8-K with Item 2.02 supplemental results and financial condition for the quarter ended June 30, 2026.

Expected impact

Low near-term impact from the excerpt alone; any trading reaction would depend on the missing tables and figures in the full exhibit.

Evidence & confidence

The text shown is largely boilerplate on non-GAAP metrics and forward-looking risks, without the actual quarter results, balance sheet figures, or key metrics.

Market effects

Sector

Limited from the excerpt; real estate REIT status change and acquisition strategy are mentioned but no new sector-wide data is provided.

Regional

None identifiable from the excerpt.

Global

None identifiable from the excerpt beyond generic geopolitical and rate-risk language.

Counterpoint

What could challenge this read

Because the excerpt lacks the actual financial tables, any apparent “results” headline may not translate into actionable trading signals until the full exhibit numbers are reviewed.

Key entities

  • public_company
    American Strategic Investment Co.

    Subject of the 8-K supplemental information for the quarter ended June 30, 2026.

  • exchange
    NYSE

    Referenced as a continued listing requirement risk if the company fails to meet rules.

Read at source← All news

Related articles

AUG 12
$VELOHighAI 9/10

Why is Velo3D stock surging today?

Velo3D shares rose about 17.2% in pre-open trading after the company reported Q2 2026 results. Revenue was $20.7 million, up 52.3% year over year and above an estimated $13.52 million. Velo3D raised full-year 2026 revenue guidance to $65 million to $75 million and expects positive EBITDA in H2 2026, with gross margin improving to 21.5% and backlog up to $31 million.

investing.com3 min
AUG 12
$HRBHighAI 9/10

Why is H&R Block stock surging today?

H&R Block (HRB) shares rose 13.9% in pre-open after reporting fiscal 2026 results. Q4 adjusted EPS was $2.38 vs $2.31 consensus. Full-year adjusted EPS rose 13.9% to $5.31 on $3.95B revenue. Fiscal 2027 adjusted EPS guidance was $6.04-$6.24, above consensus. Board raised quarterly dividend to $0.46 and approved a $500.3M buyback.

investing.com3 min
AUG 12
$AMCRHigh

Amcor plc (AMCR): Results of Operations and Financial Condition

Amcor plc (AMCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 amcor4q2026ex991-june302026.htm EX-99.1 Document Exhibit 99.1 Amcor Reports Strong Fourth Quarter and Full-Year Results Highlights - Three Months Ended June 30, 2026 • Net sales $6.4 billion, up 26% largely driven by Berry acquisition and pass through of higher raw mate

SEC EDGAR 8-K6 min
AUG 12
$BETAHighAI 9/10

BETA Technologies, Inc. (BETA): Results of Operations and Financial Condition

BETA Technologies, Inc. (BETA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q2earningsrelease.htm EX-99.1 Document BETA Technologies, Inc. Announces Second Quarter 2026 Results Delivered strong revenue growth and continued momentum across its commercial, defense and integrated aerospace platform. SOUTH BURLINGTON, Vt. – August 12, 2026 – B

SEC EDGAR 8-K6 min
AUG 12
$EYEHigh

National Vision Holdings, Inc. (EYE): Results of Operations and Financial Condition

National Vision Holdings, Inc. (EYE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex991-q22026earningsrelease.htm EX-99.1 Document Exhibit 99.1 National Vision Holdings, Inc. Reports Second Quarter 2026 Financial Results Strategic Transformation Delivers Accelerated Profitability Raises Full-Year Adjusted Operating Income and Tightens Adjusted Compar

SEC EDGAR 8-K6 min
AUG 12
$AARDMed

Why is Aardvark Therapeutics stock surging today?

Aardvark Therapeutics (AARD) shares rose 11.1% in pre-open after the company reported Q2 2026 results on Aug. 11. According to the article, EPS beat expectations by $0.21 versus consensus of -$0.88. Aardvark reported $73.9M cash and said it remains in active FDA discussions to resolve the ARD-101 clinical hold.

investing.com4 min
American Strategic Investment Co. (NYC): Results of Operations and Financial Condition — alphai